Registry-listed formulations

Oxitriptan · chembl:CHEMBL350221

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

8 source entries across 6 studies. This list may not include all unresolved or historical entries.

  • 5-HTPRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 5-HydroxytryptophanRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 5-Hydroxytryptophan 100 MGRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 5-HydroxytryptophanRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 5-HydroxytryptophanRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Cincofarm 100 mg CápsulasRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Low Dose 5-hydroxytryptophanRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • High Dose 5-hydroxytryptophanRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
33%(1 trials)

Phase Distribution

Not Applicable
1
17%
Phase 2/3
1
17%
Phase 2
4
67%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 2/3Combined phases
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

Phase 24 (66.7%)
Phase 2/31 (16.7%)
N/A1 (16.7%)

Trials by Status

recruiting233%
active_not_recruiting117%
completed350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

5HTP Regulation Of Asthma In Children

NCT04160910
active_not_recruitingphase_2_3

Effects of 5HTP on the Injured Human Spinal Cord

NCT04520178
recruitingphase_2

5-HTP and Creatine for Depression R33 Phase

NCT05895747
completedphase_2

ERG/5-HTP in Fragile X Syndrome (FXS)

NCT05030129
completedphase_2

5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores

NCT03574948
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04160910Phase 2

5HTP Regulation Of Asthma In Children

Recruiting
NCT04520178Phase 2/3

Effects of 5HTP on the Injured Human Spinal Cord

Active Not Recruiting
NCT05895747Phase 2

5-HTP and Creatine for Depression R33 Phase

Recruiting
NCT05030129Phase 2

ERG/5-HTP in Fragile X Syndrome (FXS)

Completed
NCT03574948Phase 2

5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores

Completed
NCT00731003Not Applicable

The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL350221

Names & Codes

ATC Classification

N06AX01

Research Codes

Dl-5-htpDl-5-hydroxytryptophanL-5-htpL-5-hydroxytryptophanNSC-92523